Trial Outcomes & Findings for Efficacy and Safety of Tenoten for Children in the Treatment of Specific Developmental Disorders of Scholastic Skills in Children (NCT NCT03159104)

NCT ID: NCT03159104

Last Updated: 2023-08-21

Results Overview

The total scholastic skill score is calculated based on the points for reading, spelling, and counting skills. Reading skills are estimated according to scale consisting of three subscales:reading speed, reading method/understanding, and reading accuracy. The minimum value of reading skills scale is 0 points, and the maximum value is 45 points. Spelling skills are estimated according to scale in 0, 15, 30, and 45 points. The minimum value is 0 points, and the maximum value is 45 points. Counting skills are estimated according to subtest No. 3 "Arithmetic" of "Wechsler Intelligence Scale for Children" (WISC) in points. The minimum value is 0 points, and the maximum value is 20 points. Total scholastic skill score is a sum of three scales (reading, spelling, and counting). The minimum value is 0 points, and the maximum value is 110 points. A higher score means the best results.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

240 participants

Primary outcome timeframe

On Day 1 and after 12 weeks of the therapy

Results posted on

2023-08-21

Participant Flow

Participant milestones

Participant milestones
Measure
Tenoten for Children
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Tenoten for children: Tablet for oral use.
Placebo
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Placebo: Tablet for oral use.
Overall Study
STARTED
122
118
Overall Study
COMPLETED
121
116
Overall Study
NOT COMPLETED
1
2

Reasons for withdrawal

Reasons for withdrawal
Measure
Tenoten for Children
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Tenoten for children: Tablet for oral use.
Placebo
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Placebo: Tablet for oral use.
Overall Study
Violation of inclusion criteria
1
2

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Tenoten for Children
n=121 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Tenoten for children: Tablet for oral use.
Placebo
n=116 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Placebo: Tablet for oral use.
Total
n=237 Participants
Total of all reporting groups
Age, Categorical
<=18 years
121 Participants
n=121 Participants
116 Participants
n=116 Participants
237 Participants
n=237 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=121 Participants
0 Participants
n=116 Participants
0 Participants
n=237 Participants
Age, Categorical
>=65 years
0 Participants
n=121 Participants
0 Participants
n=116 Participants
0 Participants
n=237 Participants
Age, Continuous
8.5 years
STANDARD_DEVIATION 0.7 • n=121 Participants
8.6 years
STANDARD_DEVIATION 0.6 • n=116 Participants
8.6 years
STANDARD_DEVIATION 0.7 • n=237 Participants
Sex: Female, Male
Female
49 Participants
n=121 Participants
46 Participants
n=116 Participants
95 Participants
n=237 Participants
Sex: Female, Male
Male
72 Participants
n=121 Participants
70 Participants
n=116 Participants
142 Participants
n=237 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
Russia
121 participants
n=121 Participants
116 participants
n=116 Participants
237 participants
n=237 Participants

PRIMARY outcome

Timeframe: On Day 1 and after 12 weeks of the therapy

The total scholastic skill score is calculated based on the points for reading, spelling, and counting skills. Reading skills are estimated according to scale consisting of three subscales:reading speed, reading method/understanding, and reading accuracy. The minimum value of reading skills scale is 0 points, and the maximum value is 45 points. Spelling skills are estimated according to scale in 0, 15, 30, and 45 points. The minimum value is 0 points, and the maximum value is 45 points. Counting skills are estimated according to subtest No. 3 "Arithmetic" of "Wechsler Intelligence Scale for Children" (WISC) in points. The minimum value is 0 points, and the maximum value is 20 points. Total scholastic skill score is a sum of three scales (reading, spelling, and counting). The minimum value is 0 points, and the maximum value is 110 points. A higher score means the best results.

Outcome measures

Outcome measures
Measure
Tenoten for Children
n=121 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Tenoten for children: Tablet for oral use.
Placebo
n=116 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Placebo: Tablet for oral use.
Mean Total Scholastic Skills Score (a Sum of Three Scales: Reading, Spelling, and Counting).
Baseline
61.39 score on a scale
Standard Deviation 12.04
60.46 score on a scale
Standard Deviation 11.04
Mean Total Scholastic Skills Score (a Sum of Three Scales: Reading, Spelling, and Counting).
After 12 weeks
79.94 score on a scale
Standard Deviation 18.22
74.56 score on a scale
Standard Deviation 18.75

SECONDARY outcome

Timeframe: On Day 1 and after 12 weeks of the therapy

Reading skills are estimated according to scale consisting of three subscales: reading speed, reading method/understanding, and reading accuracy. Students of 7 years old are invited to read the words, and students of 8-9 years old are invited to read a small text. Speed, method, and accuracy of the reading are estimated in students of 7 years old. Speed, accuracy, and understanding of the text are estimated in students of 8-9 years old. The minimum value is 0 points, and the maximum value is 45 points. A higher score meant the best results.

Outcome measures

Outcome measures
Measure
Tenoten for Children
n=121 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Tenoten for children: Tablet for oral use.
Placebo
n=116 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Placebo: Tablet for oral use.
Mean Reading Skills Score
Baseline
27.69 score on a scale
Standard Deviation 6.52
27.76 score on a scale
Standard Deviation 6.16
Mean Reading Skills Score
After 12 weeks
34.96 score on a scale
Standard Deviation 6.66
33.66 score on a scale
Standard Deviation 7.7

SECONDARY outcome

Timeframe: On Day 1 and after 12 weeks of the therapy

Spelling skills are estimated according to scale in 0, 15, 30, and 45 points. Students of 7 years old are invited to write dictated letters, their names, and three words (mom, table, trunk), and students of 8-9 years old are invited to write a small dictation. Dysgraphic errors and their types as well as the number of non-dysgraphic errors are taken into consideration for estimation. The minimum value is 0 points, and the maximum value is 45 points. A higher score meant the best results.

Outcome measures

Outcome measures
Measure
Tenoten for Children
n=121 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Tenoten for children: Tablet for oral use.
Placebo
n=116 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Placebo: Tablet for oral use.
Mean Score Spelling Skills Score
Baseline
22.56 score on a scale
Standard Deviation 7.53
21.59 score on a scale
Standard Deviation 7.48
Mean Score Spelling Skills Score
After 12 weeks
32.73 score on a scale
Standard Deviation 13.69
29.09 score on a scale
Standard Deviation 14.58

SECONDARY outcome

Timeframe: On Day 1 and after 12 weeks of the therapy

Counting skills are estimated according to subtest No. 3 "Arithmetic" of "Wechsler Intelligence Scale for Children" (WISC) in points. "Arithmetic" subtest includes 16 tasks from elementary school arithmetic which are tackled verbally. Easiness of operating numbers, accuracy, and time spent on the tasks are estimated. Each task is rated in points (0 or 1), by the end of testing and rating for each task the sum of points (raw score) is calculated and converted into a scale score using standard tables. The minimum value is 0 points, and the maximum value is 20 points. A higher score meant the best results.

Outcome measures

Outcome measures
Measure
Tenoten for Children
n=121 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Tenoten for children: Tablet for oral use.
Placebo
n=116 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Placebo: Tablet for oral use.
Mean Counting Skills Score.
Baseline
11.14 score on a scale
Standard Deviation 2.24
11.10 score on a scale
Standard Deviation 2.27
Mean Counting Skills Score.
After 12 weeks
12.26 score on a scale
Standard Deviation 2.80
11.80 score on a scale
Standard Deviation 2.73

SECONDARY outcome

Timeframe: On Day 1 and after 12 weeks of the therapy

Percentage of children with an increase in total scholastic skills score (a sum of three scales: reading, spelling, and counting). Total scholastic skill score is a sum of three scales (reading, spelling, and counting). The minimum value is 0 points, and the maximum value is 110 points. A higher score meant the best results. The increase in total scholastic skills score means an increasing by at least 5 points compared to baseline.

Outcome measures

Outcome measures
Measure
Tenoten for Children
n=121 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Tenoten for children: Tablet for oral use.
Placebo
n=116 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Placebo: Tablet for oral use.
Percentage of Children With an Increase in Total Scholastic Skills Score (a Sum of Three Scales: Reading, Spelling, and Counting).
103 Participants
80 Participants

SECONDARY outcome

Timeframe: In 12 weeks of the treatment.

Population: The number of patients who have data on the CGI-EI scale is indicated.

The Clinical Global Impression-Efficiency Index (CGI-E) scale consists of two subscales. Efficacy subscale measures efficacy of medicine based on the severity of symptoms at the end of therapy. The minimum value is 1 points, and the maximum value is 4 points. A higher score means the best results. Side effects subscale measures side effects of the medicine. The minimum value is 1 points, and the maximum value is 4 points. A higher score means the best results. The scale is filled in by the doctor at the final visit after 12 weeks of the treatment. In accordance with the results of treatment, the doctor expresses his opinion about the efficacy of the therapy and the degree of medicine safety, making marks in the appropriate columns of the table. The efficacy index is determined as intersection of columns of indicators of efficacy and side effects in the table. The minimum value is 0.25 points, and the maximum value is 4 points. A higher score means the best results.

Outcome measures

Outcome measures
Measure
Tenoten for Children
n=118 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Tenoten for children: Tablet for oral use.
Placebo
n=112 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Placebo: Tablet for oral use.
Efficacy Index According to Clinical Global Impression Scale.
2.36 score on a scale
Standard Deviation 0.87
1.98 score on a scale
Standard Deviation 0.83

Adverse Events

Tenoten for Children

Serious events: 0 serious events
Other events: 42 other events
Deaths: 0 deaths

Placebo

Serious events: 2 serious events
Other events: 29 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Tenoten for Children
n=122 participants at risk
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Tenoten for children: Tablet for oral use.
Placebo
n=118 participants at risk
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Placebo: Tablet for oral use.
Infections and infestations
Phlegmonous appendicitis
0.00%
0/122 • During the treatment period - 12 weeks.
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
Infections and infestations
Bacterial pneumonia
0.00%
0/122 • During the treatment period - 12 weeks.
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.

Other adverse events

Other adverse events
Measure
Tenoten for Children
n=122 participants at risk
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Tenoten for children: Tablet for oral use.
Placebo
n=118 participants at risk
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal. Placebo: Tablet for oral use.
Ear and labyrinth disorders
Hearing loss
0.00%
0/122 • During the treatment period - 12 weeks.
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
Eye disorders
Eye pain
0.00%
0/122 • During the treatment period - 12 weeks.
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
Gastrointestinal disorders
Functional indigestion
0.00%
0/122 • During the treatment period - 12 weeks.
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
Gastrointestinal disorders
Abdominal pain
1.6%
2/122 • Number of events 2 • During the treatment period - 12 weeks.
4.2%
5/118 • Number of events 5 • During the treatment period - 12 weeks.
Gastrointestinal disorders
Diarrhea
1.6%
2/122 • Number of events 2 • During the treatment period - 12 weeks.
3.4%
4/118 • Number of events 4 • During the treatment period - 12 weeks.
Gastrointestinal disorders
Dyspepsia
0.00%
0/122 • During the treatment period - 12 weeks.
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
Gastrointestinal disorders
Food intoxication
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
0.00%
0/118 • During the treatment period - 12 weeks.
Gastrointestinal disorders
Nausea
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
Gastrointestinal disorders
Stomatitis
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
Gastrointestinal disorders
Vomiting
0.00%
0/122 • During the treatment period - 12 weeks.
1.7%
2/118 • Number of events 2 • During the treatment period - 12 weeks.
General disorders
Hyperthermia
1.6%
2/122 • Number of events 2 • During the treatment period - 12 weeks.
0.00%
0/118 • During the treatment period - 12 weeks.
Immune system disorders
Pseudoallergy
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
0.00%
0/118 • During the treatment period - 12 weeks.
Infections and infestations
Gastroenteritis
1.6%
2/122 • Number of events 2 • During the treatment period - 12 weeks.
0.00%
0/118 • During the treatment period - 12 weeks.
Infections and infestations
Gingivitis
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
0.00%
0/118 • During the treatment period - 12 weeks.
Infections and infestations
Laryngitis
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
0.00%
0/118 • During the treatment period - 12 weeks.
Infections and infestations
Nasopharyngitis
1.6%
2/122 • Number of events 2 • During the treatment period - 12 weeks.
4.2%
5/118 • Number of events 5 • During the treatment period - 12 weeks.
Infections and infestations
Herpes labial
0.00%
0/122 • During the treatment period - 12 weeks.
1.7%
2/118 • Number of events 2 • During the treatment period - 12 weeks.
Infections and infestations
Pharyngitis
2.5%
3/122 • Number of events 3 • During the treatment period - 12 weeks.
1.7%
2/118 • Number of events 2 • During the treatment period - 12 weeks.
Infections and infestations
ARI
5.7%
7/122 • Number of events 7 • During the treatment period - 12 weeks.
3.4%
4/118 • Number of events 4 • During the treatment period - 12 weeks.
Infections and infestations
ARVI
11.5%
14/122 • Number of events 14 • During the treatment period - 12 weeks.
5.1%
6/118 • Number of events 6 • During the treatment period - 12 weeks.
Infections and infestations
Rhinitis
3.3%
4/122 • Number of events 4 • During the treatment period - 12 weeks.
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
Infections and infestations
Runny nose
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
0.00%
0/118 • During the treatment period - 12 weeks.
Infections and infestations
Sinusitis
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
0.00%
0/118 • During the treatment period - 12 weeks.
Infections and infestations
Tonsillitis
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
Injury, poisoning and procedural complications
Ankle fracture
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
0.00%
0/118 • During the treatment period - 12 weeks.
Nervous system disorders
Headache
3.3%
4/122 • Number of events 4 • During the treatment period - 12 weeks.
4.2%
5/118 • Number of events 5 • During the treatment period - 12 weeks.
Nervous system disorders
Hyperactivity
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
Nervous system disorders
Tremor
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
0.00%
0/118 • During the treatment period - 12 weeks.
Psychiatric disorders
Hyperexcitability syndrome
0.00%
0/122 • During the treatment period - 12 weeks.
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
Psychiatric disorders
Enuresis
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
0.00%
0/118 • During the treatment period - 12 weeks.
Psychiatric disorders
Insomnia
1.6%
2/122 • Number of events 2 • During the treatment period - 12 weeks.
0.00%
0/118 • During the treatment period - 12 weeks.
Psychiatric disorders
Obsessions
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
0.00%
0/118 • During the treatment period - 12 weeks.
Psychiatric disorders
Simple vocal tics
0.00%
0/122 • During the treatment period - 12 weeks.
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
Respiratory, thoracic and mediastinal disorders
Bronchial asthma
0.00%
0/122 • During the treatment period - 12 weeks.
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
Respiratory, thoracic and mediastinal disorders
Bronchitis
0.00%
0/122 • During the treatment period - 12 weeks.
1.7%
2/118 • Number of events 2 • During the treatment period - 12 weeks.
Respiratory, thoracic and mediastinal disorders
Cough
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
0.00%
0/118 • During the treatment period - 12 weeks.
Respiratory, thoracic and mediastinal disorders
Nose bleed
0.00%
0/122 • During the treatment period - 12 weeks.
2.5%
3/118 • Number of events 3 • During the treatment period - 12 weeks.
Respiratory, thoracic and mediastinal disorders
Runny nose
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
0.00%
0/118 • During the treatment period - 12 weeks.
Respiratory, thoracic and mediastinal disorders
Vasomotor rhinitis
0.00%
0/122 • During the treatment period - 12 weeks.
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
Skin and subcutaneous tissue disorders
Allergic dermatitis
4.1%
5/122 • Number of events 5 • During the treatment period - 12 weeks.
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
Skin and subcutaneous tissue disorders
Pitiriasis pink
0.00%
0/122 • During the treatment period - 12 weeks.
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.

Additional Information

Mikhail Putilovskiy, MD, PhD, Clinical and Medical Department Director

MATERIA MEDICA HOLDING

Phone: +74952761571

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: OTHER